How Do Mounjaro and Ozempic Work for Weight Loss?
Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist that mimics two gut hormones to reduce appetite, slow digestion, and improve insulin sensitivity. Ozempic (semaglutide) is a GLP-1 receptor agonist that targets one hormone for similar effects but without the GIP component. Both are weekly injections originally for type 2 diabetes but used off-label for weight loss; Mounjaro's higher doses are approved under Zepbound specifically for obesity.
What Do Clinical Trials Show for Weight Loss?
In head-to-head data from Eli Lilly's SURMOUNT-5 trial (825 adults with obesity or overweight), Mounjaro led to 20.2% average weight loss over 72 weeks versus 13.7% with Ozempic at maximum doses (15mg tirzepatide vs. 2.4mg semaglutide). [1] This 6.5% difference was statistically significant (p<0.001).
Earlier trials align: SURMOUNT-1 showed Mounjaro at 15mg yielding 22.5% loss over 72 weeks; STEP-1 for Wegovy (higher-dose semaglutide) showed 14.9%. [2][3] About 91% of Mounjaro users lost ≥5% body weight vs. 75% on Ozempic in SURMOUNT-5.
| Trial/Drug | Dose | % Weight Loss (72 weeks) | ≥15% Loss Achieved |
|------------|------|---------------------------|---------------------|
| SURMOUNT-5 Mounjaro | 15mg | 20.2% | 62% |
| SURMOUNT-5 Ozempic | 2.4mg | 13.7% | 38% |
| SURMOUNT-1 Mounjaro | 15mg | 22.5% | 69% |
| STEP-1 Wegovy | 2.4mg | 14.9% | 50% |
Why Might Mounjaro Lead to More Weight Loss?
The dual mechanism boosts effects: GIP enhances GLP-1's fat metabolism and fullness signals. Real-world data from a 2024 study of 18,000 patients showed Mounjaro users losing 15.3% vs. 8.3% for Ozempic over 12 months. [4] Higher tolerated doses (up to 15mg vs. Ozempic's 2.4mg) contribute, though gastrointestinal side effects like nausea limit some patients.
What About Side Effects and Who It Works Best For?
Both cause nausea (20-40% of users), vomiting, diarrhea, and constipation; Mounjaro's rates are similar or slightly higher early on but may fade faster. [1] Serious risks like pancreatitis or thyroid tumors are rare for both (black-box warnings apply). Mounjaro edges out for diabetes patients due to better A1C drops (2.3% vs. 1.9%). [2] No clear winner for non-diabetics—response varies by genetics, diet adherence, and starting weight.
Cost and Access Differences
Mounjaro/Zepbound lists at $1,086/month without insurance; Ozempic at $936. [5] Compounded versions cut costs to $200-400 but face FDA shortages scrutiny. Insurance covers Ozempic more for diabetes; weight-loss approval favors Zepbound.
Real Patient Experiences
Forums like Reddit report Mounjaro users averaging 1-2 lbs/week loss vs. 0.5-1 lb on Ozempic, but 20-30% switch due to side effects or plateaus. [6] Long-term data beyond 18 months is limited.
Bottom Line: Is Mounjaro Better?
Mounjaro shows superior average weight loss (15-20% vs. 10-15%) in trials and real-world use, driven by its dual action. Individual results differ—start with doctor input, as neither guarantees success without lifestyle changes.
Sources:
[1] NEJM: SURMOUNT-5 Trial (2024)
[2] NEJM: SURMOUNT-1 (2022)
[3] NEJM: STEP-1 (2021)
[4] JAMA: Real-World Comparison (2024)
[5] Drugs.com Pricing
[6] Reddit User Reports (aggregated)